Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer

British Journal of Cancer

Volumn 87, Issue 12, 2002, Pages 1437-1444

  Salgado, R ^a,b   Benoy, I ^a,b   Weytjens, R ^b   Van Bockstaele, D ^b   Van Marck, E ^b   Huget, Ph ^a   Hoylaerts, M ^c   Vermeulen, P ^a,b   Dirix, Luc Y ^a  

^a SINT AUGUSTINUS HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

D dimers; Fibrinolysis; Interleukin 6; VEGF A

Indexed keywords

D DIMER; FIBRIN; FIBRINOGEN; INTERLEUKIN 6; VASCULOTROPIN;

ANGIOGENESIS; ARTERY; ARTICLE; CANCER; CELL LINE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOPLASM; DEVELOPMENT; ENDOTHELIUM; FIBRINOGEN METABOLISM; HEMOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEGAKARYOBLAST; MEGAKARYOCYTE; MESENTERIC VEIN; OVARY CARCINOMA; PERIPHERAL VEIN; PRIORITY JOURNAL; STROMA; THROMBOCYTE; TUMOR CELL; UPREGULATION; UTERINE BLOOD VESSEL; UTERINE CERVIX CARCINOMA;

BLOOD COAGULATION TESTS; BLOOD PLATELETS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0037011659     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600655     Document Type: Article

References (51)

1. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Waiters C, Selby PJ (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77: 956-964
2. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY (2002) Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2: 311-315
3. Bobik R, Hong Y, Breier G, Martin JF, Erusalimsky JD (1998) Thrombopoietin stimulates VEGF release from c-Mpl-expressing cell lines and haematopoietic progenitors. FEBS Lett 423: 10-14
4. Borden EC, Chin P (1994) Interleukin-6: A cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med 123: 824-829
5. Carmeliet P, Collen D (1998) Development and disease in proteinase-deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 91: 255-285
6. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
7. Cohen T, Nahari D, Cerem LW, Neufeld G., Levi BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271: 736-741
8. Contrino J, Goralnick S, Qi J, Hair G, Rickles FR, Kreutzer DL (1997) Fibrin induction of tissue factor expression in human vascular endothelial cells. Circulation 96: 605-613
9. De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E, Catalano G (2001) Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 21: 45-52
10. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prove A, Lemmens J, Vermeulen P (2002) Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 86: 389-395
11. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M, Van Oosterom AT (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76: 238-243
12. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039
13. Dvorak HF, Harvey VS, McDonagh J (1984) Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res 44: 3348-3354
14. Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, Cornell CJ, Forcier RJ, O'Donnell JF, Headley E (1987) Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 88: 596-602
15. Eppler SM, Combs DL, Henry, TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF (2002) A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 71: 20-32
16. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G (2000) Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58: 169-174
17. Hirano T (1999) Molecular basis underlying functional pleiotropy of cytokines and growth factors. Biochem Biophys Res Commun 260: 303-308
18. Imai T, Koike K, Kubo T, Kikuchi T, Amano Y, Takagi M, Okumura N, Nakahata T (1991) Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood 78: 1969-1974
19. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y (1989) Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74: 1241-1244
20. Kalweit GA, Feindt P, Micek M, Gams E, Hellstern P (2000) Markers of activated hemostasis and fibrinolysis in patients with pulmonary malignancies: Comparison of plasma levels in central venous and pulmonary venous blood. Thromb Res 97: 105-111
21. Kellar KL, Hooper WC, Benson JM (1995) MEG-01s cells have receptors for and respond to IL-3, IL-6, and SCF. Exp Hematol 23: 557-564
22. Kudryk BJ, Bini A (2000) Monoclonal antibody designated T2G1 reacts with human fibrin beta-chain but not with the corresponding chain from mouse fibrin. Arterioscler Thromb Vasc Biol 20: 1848-1849
23. Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F, Barone C (1998) Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 78: 765-770
24. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309
25. Ljungberg B, Grankvist K, Rasmuson T (1997) Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 33: 1794-1798
26. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E (1999) Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 93: 3811-3823
27. Mielicki W, Serwa J, Kurzawinski T, Wierzbicki R (1990) Procoagulant activity of human stomach and colon cancers. Oncology 47: 299-302
28. Mohle R, Green D, Moore MA, Nachman RL, Rafii S (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94: 663-668
29. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, Dvorak HF (1989) Pathogenesis of tumor stroma generation: A critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acra 948: 305-326
30. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF (1995) Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 55: 376-385
31. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706
32. Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M, Kotzsch M, Schomig A (1997) Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 17: 3399-3405
33. O'Byrne KJ, Dobbs N, Harris AL (2000) Serum vascular endothelial growth factor load and interleukin-6 in cancer patients. Br J Cancer 82: 1895-1896
34. Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H, Saito H (1985) Establishment of a novel human megakaryoblastic leukemia cell line, MEG- 01, with positive Philadelphia chromosome. Blood 66: 1384-1392
35. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J (1998) Involvement of platelets in tumour angiogenesis?. Lancet 352: 1775-1777
36. Rybarczyk BJ, Simpson-Haidaris PJ (2000) Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells. Crower Res 60: 2033-2039
37. Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L, Van Marck E (2001) Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study. Angiogenesis 4: 37-43
38. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80: 892-897
39. Salven P, Orpana A, Joensuu H (1999) Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5: 487-491
40. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD (1997) Interleukin-6: Structure-function relationships. Protein Sci 6: 929-955
41. Steinberg MH, Kelton JG, Coller BS (1987) Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. N Engl J Med 317: 1037-1042
42. Stirk CM, Reid A, Melvin WT, Thompson WD (2000) Locating the active site for angiogenesis and cell proliferation due to fibrin fragment E with a phage epitope display library. Gen Pharmacol 35: 261-267
43. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C (1997) Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 66: 27-30
44. Thompson WD, Campbell R, Evans T (1985) Fibrin degradation and angiogenesis: Quantitative analysis of the angiogenic response in the chick chorioallantoic membrane. J Pathol 145: 27-37
45. Turley H, Scott PA, Watts VM, Bicknell R, Harris AL, Garter KC (1998) Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 186: 313-318
46. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60: 203-212
47. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, Pinedo HM (2000a) Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 6: 166-171
48. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM (1997) Platelet: Transporter of vascular endothelial growth factor. Clin Cancer Res 3: 2187-2190
49. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM (2000b) Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96: 4216-4221
50. Werther K, Bülow S, Hesselfeldt P, Jespersen N, Svendsen MN, Nielsen HJ (2001) VEGF concentrations in tumour arteries and veins from patients with rectal cancer. Euroconference on Angiogenesis, Paris abstract nr. C-19
51. Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T (1998) Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol 28: 740-744